2026.07.01
Reforgene named among China's Top 100 Innovative Pharmaceutical Companies 2026
Reforgene was recognized as one of China's Top 100 Innovative Pharmaceutical Companies for 2026.
Latest Updates
Reforgene named a Future Healthcare Top 100 company for the fourth consecutive year
Reforgene has been listed among the Future Healthcare Top 100 for four consecutive years.
TIF and the Angel Mama Foundation visit Reforgene to advance global access for thalassemia gene medicine
The Thalassaemia International Federation (TIF) and the Angel Mama Foundation visited Reforgene to jointly advance globalization and patient access for thalassemia gene medicines.
Reforgene approved as a postdoctoral research workstation sub-station
Reforgene was approved to establish a postdoctoral research workstation sub-station, strengthening its talent base for gene editing medicine innovation.
Reforgene listed among China's 2025 biopharma frontrunners
Reforgene was named to the 2025 China Biopharmaceutical Frontrunner list.
Reforgene named a 2024 Top 50 most influential healthcare company
Reforgene was recognized as one of the most influential healthcare companies of 2024.
Reforgene named a 2025 Future Healthcare Top 100 company for the third consecutive year
Reforgene was listed among the 2025 Future Healthcare Top 100 for the third consecutive year.
World Thalassemia Day: Reforgene contributes China's innovative medicine solutions toward a thalassemia-free world
On World Thalassemia Day, Reforgene shared China's innovative medicine solutions in pursuit of a thalassemia-free world.
Guangzhou Industrial Investment Group visits Reforgene
Guangzhou Industrial Investment Group visited Reforgene to explore the future of the gene editing industry.
View all news (38 items)
2024.12.30